Gradient Bioconvergence (CEO Jin-Geun Lee) announced that it received attention from academia and industry by introducing its latest research results through three poster presentations at the American Association for Cancer Research Annual Meeting (AACR 2025), held in Chicago, USA from the 25th to the 30th (local time).
GBC-11004, which was first unveiled through a poster presentation at this conference, is a new target derived from Gradient Bioconvergence's own big data of over 800 global cancer patient-derived organoids (PDO) and AI-based target discovery platform. It is a new kinase that is overexpressed in non-small cell lung cancer (NSCLC) patients who are resistant to third-generation EGFR inhibitors. In particular, when the GBC-11004 inhibitor was administered in combination with existing third-generation EGFR inhibitors, a significant improvement in suppressing resistance response was observed, focusing the attention of the site.
“Lung cancer has the highest incidence rate in the world, and resistance to most targeted therapies, including EGFR inhibitors, remains an unresolved challenge,” said Jin-Geun Lee, CEO of Gradient Bioconvergence. “This study is an important case that has confirmed the potential of GBC-11004 as a new therapeutic target related to this resistance. We plan to gradually expand preclinical and clinical studies through joint development with global pharmaceutical companies in the future, and continue R&D with the goal of transitioning to a practical treatment alternative.”
In addition, Gradient Bioconvergence attracted great interest from visitors by introducing its cancer organoid banking through individual booths and separate poster presentations. With an average of 50 partnering meetings held per day, the immune cell and vascular cell co-culture model that realistically implemented the tumor microenvironment attracted great attention from industry insiders, and was especially highly evaluated for the fact that AI technology led to the discovery of practical candidate substances.
- See more related articles
You must be logged in to post a comment.